Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression

Liu Yang, Dongdong Fang, Huijun Chen, Yiyu Lu, Zheng Dong, Han Fei Ding, Qing Jing, Shi Bing Su, Shuang Huang

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

CCNE1 gene amplification is present in 15-20% ovary tumor specimens. Here, we showed that Cyclin E1 (CCNE1) was overexpressed in 30% of established ovarian cancer cell lines. We also showed that CCNE1 was stained positive in over 40% of primary ovary tumor specimens regardless of their histological types while CCNE1 staining was either negative or low in normal ovary and benign ovary tumor tissues. However, the status of CCNE1 overexpression was not associated with the tumorigenic potential of ovarian cancer cell lines and also did not correlate with pathological grades of ovary tumor specimens. Subsequent experiments with CCNE1 siRNAs showed that knockdown of CCNE1 reduced cell growth only in cells with inherent CCNE1 overexpression, indicating that these cells may have developed an addiction to CCNE1 for growth/survival. As CCNE1 is a regulatory factor of cyclin-dependent kinase 2 (Cdk2), we investigated the effect of Cdk2 inhibitor on ovary tumorigenecity. Ovarian cancer cells with elevated CCNE1 expression were 40 times more sensitive to Cdk2 inhibitorSNS-032 than those without inherent CCNE1 overexpression. Moreover, SNS-032 greatly prolonged the survival of mice bearing ovary tumors with inherent CCNE1 overexpression. This study suggests that ovary tumors with elevated CCNE1 expression may be staged for Cdk2-targeted therapy.

Original languageEnglish (US)
Pages (from-to)20801-20812
Number of pages12
JournalOncotarget
Volume6
Issue number25
DOIs
StatePublished - Jan 1 2015

Fingerprint

Cyclin-Dependent Kinase 2
Cyclins
Ovary
Neoplasms
Ovarian Neoplasms
Cell Line
Gene Amplification
Growth

Keywords

  • CCNE1
  • Cdk2
  • Ovarian cancer
  • Tumor development

ASJC Scopus subject areas

  • Oncology

Cite this

Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression. / Yang, Liu; Fang, Dongdong; Chen, Huijun; Lu, Yiyu; Dong, Zheng; Ding, Han Fei; Jing, Qing; Su, Shi Bing; Huang, Shuang.

In: Oncotarget, Vol. 6, No. 25, 01.01.2015, p. 20801-20812.

Research output: Contribution to journalArticle

Yang, Liu ; Fang, Dongdong ; Chen, Huijun ; Lu, Yiyu ; Dong, Zheng ; Ding, Han Fei ; Jing, Qing ; Su, Shi Bing ; Huang, Shuang. / Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression. In: Oncotarget. 2015 ; Vol. 6, No. 25. pp. 20801-20812.
@article{6761207c3e1a4fd4aeb2ba61099d2258,
title = "Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression",
abstract = "CCNE1 gene amplification is present in 15-20{\%} ovary tumor specimens. Here, we showed that Cyclin E1 (CCNE1) was overexpressed in 30{\%} of established ovarian cancer cell lines. We also showed that CCNE1 was stained positive in over 40{\%} of primary ovary tumor specimens regardless of their histological types while CCNE1 staining was either negative or low in normal ovary and benign ovary tumor tissues. However, the status of CCNE1 overexpression was not associated with the tumorigenic potential of ovarian cancer cell lines and also did not correlate with pathological grades of ovary tumor specimens. Subsequent experiments with CCNE1 siRNAs showed that knockdown of CCNE1 reduced cell growth only in cells with inherent CCNE1 overexpression, indicating that these cells may have developed an addiction to CCNE1 for growth/survival. As CCNE1 is a regulatory factor of cyclin-dependent kinase 2 (Cdk2), we investigated the effect of Cdk2 inhibitor on ovary tumorigenecity. Ovarian cancer cells with elevated CCNE1 expression were 40 times more sensitive to Cdk2 inhibitorSNS-032 than those without inherent CCNE1 overexpression. Moreover, SNS-032 greatly prolonged the survival of mice bearing ovary tumors with inherent CCNE1 overexpression. This study suggests that ovary tumors with elevated CCNE1 expression may be staged for Cdk2-targeted therapy.",
keywords = "CCNE1, Cdk2, Ovarian cancer, Tumor development",
author = "Liu Yang and Dongdong Fang and Huijun Chen and Yiyu Lu and Zheng Dong and Ding, {Han Fei} and Qing Jing and Su, {Shi Bing} and Shuang Huang",
year = "2015",
month = "1",
day = "1",
doi = "10.18632/oncotarget.4600",
language = "English (US)",
volume = "6",
pages = "20801--20812",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "25",

}

TY - JOUR

T1 - Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression

AU - Yang, Liu

AU - Fang, Dongdong

AU - Chen, Huijun

AU - Lu, Yiyu

AU - Dong, Zheng

AU - Ding, Han Fei

AU - Jing, Qing

AU - Su, Shi Bing

AU - Huang, Shuang

PY - 2015/1/1

Y1 - 2015/1/1

N2 - CCNE1 gene amplification is present in 15-20% ovary tumor specimens. Here, we showed that Cyclin E1 (CCNE1) was overexpressed in 30% of established ovarian cancer cell lines. We also showed that CCNE1 was stained positive in over 40% of primary ovary tumor specimens regardless of their histological types while CCNE1 staining was either negative or low in normal ovary and benign ovary tumor tissues. However, the status of CCNE1 overexpression was not associated with the tumorigenic potential of ovarian cancer cell lines and also did not correlate with pathological grades of ovary tumor specimens. Subsequent experiments with CCNE1 siRNAs showed that knockdown of CCNE1 reduced cell growth only in cells with inherent CCNE1 overexpression, indicating that these cells may have developed an addiction to CCNE1 for growth/survival. As CCNE1 is a regulatory factor of cyclin-dependent kinase 2 (Cdk2), we investigated the effect of Cdk2 inhibitor on ovary tumorigenecity. Ovarian cancer cells with elevated CCNE1 expression were 40 times more sensitive to Cdk2 inhibitorSNS-032 than those without inherent CCNE1 overexpression. Moreover, SNS-032 greatly prolonged the survival of mice bearing ovary tumors with inherent CCNE1 overexpression. This study suggests that ovary tumors with elevated CCNE1 expression may be staged for Cdk2-targeted therapy.

AB - CCNE1 gene amplification is present in 15-20% ovary tumor specimens. Here, we showed that Cyclin E1 (CCNE1) was overexpressed in 30% of established ovarian cancer cell lines. We also showed that CCNE1 was stained positive in over 40% of primary ovary tumor specimens regardless of their histological types while CCNE1 staining was either negative or low in normal ovary and benign ovary tumor tissues. However, the status of CCNE1 overexpression was not associated with the tumorigenic potential of ovarian cancer cell lines and also did not correlate with pathological grades of ovary tumor specimens. Subsequent experiments with CCNE1 siRNAs showed that knockdown of CCNE1 reduced cell growth only in cells with inherent CCNE1 overexpression, indicating that these cells may have developed an addiction to CCNE1 for growth/survival. As CCNE1 is a regulatory factor of cyclin-dependent kinase 2 (Cdk2), we investigated the effect of Cdk2 inhibitor on ovary tumorigenecity. Ovarian cancer cells with elevated CCNE1 expression were 40 times more sensitive to Cdk2 inhibitorSNS-032 than those without inherent CCNE1 overexpression. Moreover, SNS-032 greatly prolonged the survival of mice bearing ovary tumors with inherent CCNE1 overexpression. This study suggests that ovary tumors with elevated CCNE1 expression may be staged for Cdk2-targeted therapy.

KW - CCNE1

KW - Cdk2

KW - Ovarian cancer

KW - Tumor development

UR - http://www.scopus.com/inward/record.url?scp=84940771081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940771081&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.4600

DO - 10.18632/oncotarget.4600

M3 - Article

C2 - 26204491

AN - SCOPUS:84940771081

VL - 6

SP - 20801

EP - 20812

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 25

ER -